ORDER A TEST Log In Contact Us
Tempus IO™

A comprehensive immunotherapy platform that provides actionable and cutting-edge services for life sciences partners advancing IO therapies, including antibody-drug conjugates (ADCs), TCR therapies, and immune checkpoint inhibitors (ICIs).

An all-in-one biomarker platform

Comprehensive real-world data (RWD)

~99% of whole transcriptome profiles contain at least one IO biomarker

Robust suite of IO biomarkers

10+ IO biomarkers available through Tempus sequencing

Advanced analytical tech

Leverage AI- and ML-based analytical tools to unlock actionable insights

Immune Profile Score (IPS)

First-of-its-kind  biomarker utilizing DNA and RNA to prognosticate ICI response

Insights delivered with every sample

Assess key aspects of the tumor microenvironment (TME) and understand resistance mechanisms using standard and novel biomarker data. Tempus IO data is included with applicable next-generation sequencing (NGS) assay orders to ensure comprehensive insights without the need for additional sample collection.

Download the Tempus IO overview to learn more

  • Tempus xT: Solid Tumor DNA Seq

    Tumor Mutational Burden (TMB)

    Microsatellite Instability (MSI)

    Neoantigen Prediction

    Human Leukocyte Antigen (HLA) Typing

    HLA Loss of Heterozygosity (LOH)

    Oncogenic Virus

    Mismatch Repair (MMR) Proteins by IHC1

    PD-L1 Protein quantification by IHC1

    Mechanisms of Tumor Resistance to Immunotherapy2

    Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)

  • Tempus xE: Whole Exome

    Tumor Mutational Burden (TMB)

    Microsatellite Instability (MSI)

    Neoantigen Prediction

    Human Leukocyte Antigen (HLA) Typing

    Oncogenic Virus

    Mismatch Repair (MMR) Proteins by IHC1

    PD-L1 Protein quantification by IHC1

    Mechanisms of Tumor Resistance to Immunotherapy2

  • Tempus xR: Whole Transcriptome RNA Seq

    Gene Expression Target Profiling3

    Neoantigen Prediction

    Immune Infiltration

    Oncogenic Virus

    T-cell Receptor / B-cell Receptor Repertoire

    Mismatch Repair (MMR) Proteins by IHC1

    PD-L1 Protein quantification by IHC1

    Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)

  • Tempus xF/xF+: Liquid Biopsies

    Blood Tumor Mutational Burden (bTMB) (xF+ only)

    Microsatellite Instability (MSI) high status (xF/xF+)

Tumor Mutational Burden (TMB)

Microsatellite Instability (MSI)

Neoantigen Prediction

Human Leukocyte Antigen (HLA) Typing

HLA Loss of Heterozygosity (LOH)

Oncogenic Virus

Mismatch Repair (MMR) Proteins by IHC1

PD-L1 Protein quantification by IHC1

Mechanisms of Tumor Resistance to Immunotherapy2

Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)

Tumor Mutational Burden (TMB)

Microsatellite Instability (MSI)

Neoantigen Prediction

Human Leukocyte Antigen (HLA) Typing

Oncogenic Virus

Mismatch Repair (MMR) Proteins by IHC1

PD-L1 Protein quantification by IHC1

Mechanisms of Tumor Resistance to Immunotherapy2

Gene Expression Target Profiling3

Neoantigen Prediction

Immune Infiltration

Oncogenic Virus

T-cell Receptor / B-cell Receptor Repertoire

Mismatch Repair (MMR) Proteins by IHC1

PD-L1 Protein quantification by IHC1

Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)

Blood Tumor Mutational Burden (bTMB) (xF+ only)

Microsatellite Instability (MSI) high status (xF/xF+)

Go beyond sequencing with powerful analytics

Tempus’ analytical capabilities leverage AI and machine learning to enhance sequencing data, enabling the identification of potential biomarkers that correlate with therapy response. Our proprietary tools uncover novel cancer dependencies and drug targets, particularly in IO-resistant populations. Tempus also offers supplementary data, custom analyses, and specialized algorithms as add-ons to meet your specific research objectives.4

Discover Tempus Lens for in-depth data and insights
image description

Understand ICI treatment response

Utilize Tempus’ Immune Profile Score (IPS), a first-of-its-kind multimodal algorithm that uses DNA and RNA to provide prognostic insights into potential outcomes following immune checkpoint inhibitor (ICI) treatment in metastatic solid tumors.

The algorithm generates a score that categorizes study participants into:

  • IPS-High: Indicates a higher likelihood of favorable outcomes with ICI treatment.
  • IPS-Low: Indicates a lower likelihood of favorable outcomes with ICI treatment.
Learn more about Immune Profile Score (IPS)
image description

Powering clinical development with data and technology

Tempus operates CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is typically completed within a median of 8 days after receiving samples.

Download our lab overview
image description

Our Science

view all
  • UPCOMING WEBINAR:

    Defining Non–Small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data

    By analyzing real-world data from NSCLC patients, this study highlights distinct differences in the tumor microenvironment between primary and acquired resistance to ICI, offering insights for developing therapies to overcome resistance.

    Read now
  • UPCOMING WEBINAR:

    Development and Validation of The Immune Profile Score (IPS), a Novel Multiomic Algorithmic Assay For Stratifying Outcomes in a Real-World Cohort of Patients With Advanced Solid Cancer Treated With Immune Checkpoint Inhibitors

    This study details the development and validation of the Immune Profile Score (IPS) algorithm. In a large, pan-cancer cohort, IPS successfully stratified patients, with IPS-High patients demonstrating significantly longer overall survival on ICI therapy.

    Read now
  • UPCOMING WEBINAR:

    Real-World Analyses To Evaluate the Role of TIGIT as a Target in First-Line (1L) Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinomas (GC/GEJC/EAC)

    Analyzing real-world data from patients with GC/GEJC/EAC revealed a high correlation between TIGIT and effector T-cell expression. This suggests that combining anti-TIGIT and anti-PD-1 therapies could enhance patient outcomes.

    Read now
  • UPCOMING WEBINAR:

    Integrating Next Generation Sequencing, EHR, and Claims Data to Extend Follow-Up in a Real-World Advanced Lung Adenocarcinoma Biomarker-Treatment Landscape

    This study shows that integrating closed claims data with electronic health records improves the completeness of treatment histories for lung cancer patients. This creates a more robust dataset for analyzing real-world treatment patterns and outcomes.

    Read now
  • UPCOMING WEBINAR:

    Real-World Experience of the Clinical Correlation Between ARID Gene Alterations /RNA Expression Levels and Treatment Benefit of Immunotherapy in Malignant Solid Tumors

    An analysis of real-world data from our clinical database at the Avera Cancer Institute explored the link between ARID gene alterations and immunotherapy outcomes, finding that patients with alterations may have improved survival compared to those without.

    Read now
  • UPCOMING WEBINAR:

    A Novel Approach To Define ctDNA Molecular Response to Immunotherapy

    An analysis of patients on ICI therapy suggests a new way to classify molecular response. Patients with consistently low ctDNA tumor fraction (<1%) have prolonged survival, similar to those with a significant decrease in ctDNA.

    Read now
  1. Assessment of MMR proteins by IHC, including MLH1, MSH2, MSH6, and PMS2, as well as PD-L1 IHC, is available as an optional add-on for Tempus xT/xE orders. This service is not automatically included in every order and should be selected by the customer.
  2. Tempus provides information on multiple variants and features that have been reported to confer resistance to immunotherapy. This includes mutations and/or copy number alterations in immune-associated genes that affect antigen presentation or interferon signaling. (xT, xE only)
  3. Tempus performs RNA whole transcriptome sequencing when sufficient tissue samples are provided.
  4. The availability of supplementary data is dependent on the scope of the request.

Trusted by hundreds of biopharma to power drug development

EXPLORE LIFE SCIENCES SOLUTIONS
EXPLORE LIFE SCIENCES SOLUTIONS

The information on this page is intended for life sciences companies and focuses on research and development applications.

Partner with us

With a broad range of laboratory services and data analysis that support immunotherapy development, Tempus has the solutions you need.